Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Investment Securities (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Gains from Investment Securities data on record, last reported at $2.4 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 44.75% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $2.4 million, down 44.75%, while the annual FY2025 figure was $1.8 million, 76.71% down from the prior year.
  • Gains from Investment Securities reached $2.4 million in Q3 2025 per AMLX's latest filing, up from $135359.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $14.2 million in Q4 2022 and bottomed at -$1.9 million in Q2 2021.
  • Average Gains from Investment Securities over 5 years is $5.3 million, with a median of $4.4 million recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: surged 736.88% in 2022, then plummeted 102.35% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $1.7 million in 2021, then soared by 736.88% to $14.2 million in 2022, then plummeted by 30.95% to $9.8 million in 2023, then crashed by 81.4% to $1.8 million in 2024, then surged by 32.76% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $2.4 million in Q3 2025, $135359.0 in Q1 2025, and $1.8 million in Q4 2024.